v1.0.0-database-resourceSchema 1.1Model ridge-safe-v2.3Benchmark repeated-fold-v2.2Build EA-20260729-15v1.0 is a database and evidence-governance release; it is not a validated disease-prediction or clinical decision-support release.
No new perturbation direction is nominated by an evidence-import audit.
Allowed registered hypotheses: not applicable.
Comparator and controls
Dataset accession and source owner.
Raw/processed availability.
Target mapping and assay context.
Primary endpoint, effect size and uncertainty.
Independent reproduction and import acceptance criteria.
Secondary endpoints
Provenance completeness.
Context match.
Negligible-effect interpretation.
Independent reproduction status.
State-transition extension
Mechanism hypothesis and registered time axis
Scientific object: perturbation × cell state × disease context × time × phenotype
Required before registration: state the proposed early molecular mediator, the expected cell-state transition and the downstream functional consequence.
6–12 hearly molecular or signalling response
planning default requires assay calibration
24–48 hregulatory program and cell-state transition
planning default requires assay calibration
4–7 ddifferentiation and functional phenotype
planning default requires assay calibration
Cell context fields
Required before registration: healthy, DMD or isogenic corrected. Required before registration: proliferating myoblast, early differentiation, fusion or maturing myotube. Required before registration; preserve donor-specific estimates.
Cell–cell consequence
Current status: not assessed. Future levels: conditioned medium; two-cell co-culture; three-dimensional muscle model; spatial perturbation model.
Blocking factors
Source study.
Assay batch.
Biological context.
Analysis version.
Assay QC thresholds
Accession resolvable.
Raw or sufficient processed data available.
Target mapping exact.
Effect, interval and denominator present.
Code/provenance sufficient for reproduction.
Evidence-import requirements
Source accession and owner.
Raw and processed data availability.
Exact denominator and exclusion flow.
Effect estimate, interval and primary contrast.
Original allocation and inferential unit.
Preregistration status.
Code and environment reproducibility.
Reagent and donor replication.
Negative-result definition.
Selective-reporting assessment.
Prospective planning fields are intentionally not applied: minimally_important_effect, negligible_effect_margin, suggested_sample_size_range, randomisation_unit.
Multiplicity and missing data
Preserve the source family and correction; do not reinterpret an isolated P value.
Define exclusions before unblinding; report all missing units and reasons; do not single-impute primary outcomes without a prespecified sensitivity analysis.
Replication rules
Not applicable unless the imported study reports multiple reagents; if so, preserve reagent-specific results.
Record whether the source result replicates across donors/samples; absence is a limitation, not a negative result.
Stop rules
Stop or classify as infeasible if a required numeric QC threshold fails.
Do not interpret a nonsignificant result as no material effect without a negligible-effect interval.
Do not change canonical candidate status automatically; require governed review.
Time and cost2–10 working days after complete source delivery; planning estimate only. Institution- and assay-dependent; obtain a local itemised quote before registration.
Preregistration statusdraft requires source accession denominator contrast and reproducibility audit
Lifecycle ruleThis draft is editable. Registration requires a timestamp and checksum; a registered revision is immutable and any correction must supersede it.
Escalation ruleRetain, release or formally change the hold only after provenance, independence and negative-evidence gates are audited.
Data-release planRelease the frozen card, protocol identifiers, analysis code, complete denominators and results irrespective of direction; never overwrite the registered card.
Boundary: This Study Card is an evidence-gated design scaffold, not a protocol, power calculation, safety claim, prediction or therapeutic recommendation.